AxCellerate provides advanced preclinical services for neuroscience research and drug development. Our work is based on Brain-on-Chip technology and three-dimensional human-derived neuronal models designed to support efficacy and safety testing, disease modelling, target validation, neurotoxicity assessment and translational research.
AxCellerate works with pharmaceutical companies, biotech companies, CROs, academic and private research institutions, and selected healthcare, food and chemical industry partners that need advanced human-relevant models for preclinical research or safety assessment.
AxCellerate is both a technology-driven company and a preclinical service partner. Our proprietary Brain-on-Chip platform is applied through specialized B2B services designed around each client’s scientific objectives.
AxCellerate is based in Switzerland and was created to bring advanced Brain-on-Chip innovation into preclinical neuroscience research and B2B service applications.
Brain-on-Chip technology is an advanced in vitro approach that uses microtechnology and human-derived neuronal models to study key aspects of brain and nervous system biology in a controlled experimental environment.
AxCellerate’s platform enables the culture, imaging and electrophysiological recording of three-dimensional human-derived neuronal models. This allows research teams to observe neuronal activity, network response and compound effects in a more human-relevant experimental setting.
AxCellerate’s technology is designed to complement existing preclinical workflows and support the use of advanced human-relevant in vitro models. It can help reduce reliance on conventional models where advanced in vitro testing adds scientific value, but it does not replace every preclinical method.
AxCellerate combines three-dimensional human-derived neuronal models, microfabricated Brain-on-Chip architecture, glass-based microtechnology and electrophysiological recording capabilities. This combination supports functional analysis of neuronal activity in a more advanced preclinical model.
AxCellerate technology is based on a Brain-on-Chip platform that combines three-dimensional human-derived neuronal models, microtechnology and functional neuronal readouts.
The main benefits include human-relevant modelling, functional analysis of neuronal activity, support for neurotoxicity assessment, disease modelling, compound screening and target validation.
Yes. AxCellerate technology can complement existing preclinical workflows by adding a more advanced and human-relevant layer of evidence.
AxCellerate offers services in Efficacy & Safety Testing, Disease Modelling and Target Validation. These services are designed to support neuroscience drug development, safety assessment, compound screening and translational research.
Efficacy & Safety Testing helps research teams evaluate compound response, safety profiles, potential neurotoxic effects and, when a suitable disease model is available, efficacy-related biological responses in human-relevant neuronal models.
Disease Modelling uses advanced neuronal models to investigate neurological disease mechanisms, disease-related biological responses and compound effects in a more relevant preclinical environment.
Target Validation helps research teams assess whether a potential therapeutic target is biologically relevant, functionally active and suitable for further development in neuroscience drug discovery programs.
AxCellerate supports neurological drug development by providing human-relevant preclinical models that help research teams evaluate compound response, safety, disease mechanisms and target biology before clinical stages.
Yes. AxCellerate’s Brain-on-Chip platform can support research into neurodegenerative disease mechanisms, neuronal activity, compound response and target validation in advanced human-derived neuronal models.
Patient-specific modelling involves adapting experimental systems around defined biological questions, mutations, disease profiles or patient-related mechanisms. AxCellerate can support these studies when suitable models and project conditions are available.
AxCellerate supports translational research by generating human-relevant preclinical evidence that helps connect experimental findings with biological mechanisms more relevant to human disease.
AxCellerate technology can support neurological drug development, neurotoxicity assessment, neurodegenerative disease models, patient-specific modelling, compound screening and translational research.
This service is used to evaluate compound response, safety profiles, potential neurotoxic effects and efficacy-related readouts when a suitable disease model is available.
It can generate human-relevant evidence that helps research teams assess potential risks, biological responses and compound effects earlier in development.
Disease Modelling uses Brain-on-Chip technology and three-dimensional human-derived neuronal models to investigate neurological disease mechanisms.
It can support studies in neurological and neurodegenerative mechanisms, compound response, patient-specific questions and translational neuroscience.
AxCellerate helps research teams investigate the biological relevance and functional impact of potential therapeutic targets in human-relevant neuronal models.
Target Validation helps reduce uncertainty before advancing a candidate or research program into more complex and costly development phases.
AxCellerate supports pharma and biotech companies with human-relevant Brain-on-Chip models for compound evaluation, disease modelling, target validation and preclinical safety assessment.
Human-relevant models can help improve the translational value of early evidence and support better-informed decisions before clinical stages.
AxCellerate can provide specialized Brain-on-Chip capabilities that complement a CRO’s existing preclinical service portfolio.
Yes. AxCellerate can support CROs in neuroscience-focused projects involving safety testing, disease modelling, target validation or translational research
Research institutions can collaborate with AxCellerate on neuroscience research, disease modelling, neurotoxicity assessment and translational research projects.
AxCellerate can support questions related to neuronal activity, disease mechanisms, compound response, target biology and patient-specific modelling.
AxCellerate can support advanced safety and neurotoxicity assessment using human-relevant neuronal models.
The platform can help investigate potential effects of compounds, ingredients, substances or formulations on neuronal activity and biological response.
AxCellerate supports neurological drug development by providing human-relevant preclinical models to investigate compound response, safety, target biology and disease mechanisms.
Brain-on-Chip technology can provide functional insights into neuronal activity and help strengthen the translational relevance of preclinical research.
Neurotoxicity assessment investigates whether a compound, substance or formulation may have adverse effects on neuronal systems.
AxCellerate uses Brain-on-Chip technology and human-derived neuronal models to observe neuronal activity, network response and potential safety-related effects.
Yes. AxCellerate can support research into neurodegenerative disease mechanisms using advanced human-relevant neuronal models.
AxCellerate technology can support research questions connected to complex neurological and neurodegenerative conditions, depending on the model and project design.
Patient-specific modelling focuses on research questions linked to specific mutations, disease profiles or patient-related biological mechanisms.
It is useful when standard models are not sufficient to investigate a specific biological question, mutation or disease-related mechanism.
AxCellerate can support compound screening by helping research teams compare candidate compounds and evaluate neuronal response in human-relevant models.
Brain-on-Chip technology can support functional readouts, parallel experimental workflows and early safety or response assessment.
AxCellerate supports translational research by generating human-relevant preclinical evidence that helps connect experimental findings with biological mechanisms relevant to human disease.
Translational relevance is important because neurological drug development requires models that better reflect human neuronal biology and disease mechanisms.
